Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 8 de 8
Filter
1.
J Clin Rheumatol ; 29(3): 165-169, 2023 Apr 01.
Article in English | MEDLINE | ID: covidwho-2261150

ABSTRACT

ABSTRACT: Telemedicine is the delivery of health care services by health care professionals using information and communication technologies to exchange valid information for the diagnosis, treatment, and prevention of diseases. Telemedicine was further developed in Latin America during the COVID-19 (coronavirus disease 2019) pandemic, becoming the first line of defense for health professionals to stop the spread of infections and allow them to continue the care of their patients. During the pandemic, 79% of rheumatologists in Latin America reported the use of remote communication, the most frequent being the use of phone calls and WhatsApp voice messages. In contrast, 84% of the patients reported that telemedicine was appropriate for them during the pandemic, but only 54% considered telemedicine to be a valid option for rheumatic health care after the pandemic. Telemedicine and telehealth have advantages such as lower costs, improved access in rural areas, shortage of care providers, and reduction in waiting time for appointments. However, it also has some challenges, such as legal, technological, and organizational barriers. In this review, we explore the current state of telemedicine in Latin America and discuss its future.


Subject(s)
COVID-19 , Rheumatology , Telemedicine , Humans , Latin America/epidemiology , SARS-CoV-2
2.
Rev. colomb. cir ; 38(1): 101-107, 20221230. tab, fig
Article in Spanish | WHO COVID, LILACS (Americas) | ID: covidwho-2236093

ABSTRACT

Introducción. La pandemia de COVID-19 replanteó la forma de atención en los sistemas de salud, afectando todas aquellas patologías no relacionadas con infecciones respiratorias, como la apendicitis aguda. El miedo al contagio por SARS-CoV-2 y las medidas restrictivas a la movilidad pudieron aumentar el tiempo desde el inicio de los síntomas hasta la consulta al servicio de urgencias, derivando en complicaciones intra y posoperatorias. Métodos. Estudio observacional descriptivo de corte trasversal y retrospectivo, donde se incluyeron todos los pacientes diagnosticados con apendicitis aguda llevados a apendicectomía, que fueron divididos en dos grupos, considerados prepandemia, desde el 1° de septiembre de 2018 al 15 de marzo de 2020, y pandemia, desde el 16 de marzo de 2020 al 30 de septiembre de 2021. Resultados. Fueron identificados 1000 pacientes, distribuidos en 501 pacientes en el grupo prepandemia y 499 en el grupo pandemia. El promedio de tiempo de consulta desde el momento de inicio de síntomas hasta consulta fue de 43 horas en el grupo prepandemia y de casi 45 horas en el grupo pandemia. Discusión. A pesar de las restricciones por la enfermedad causada por el nuevo coronavirus y el miedo que puede existir por el contagio, en nuestro centro no se evidenció un cambio en el manejo y presentación de los pacientes diagnosticados con apendicitis aguda


Introduction. The COVID-19 pandemic varied the way health systems were attended, thus affecting pathologies not related to respiratory infections, such as acute appendicitis. Fear of SARS-CoV-2 infection and mobility restrictive measures may have implied a longer time from the onset of symptoms to consultation of the emergency department, leading to intraoperative and postoperative complications. Methods. Retrospective cross-sectional descriptive observational study, identifying all patients diagnosed with acute appendicitis and taken for appendectomy, divided into two groups, considered pre-pandemic, from September 1, 2018 to March 15, 2020, and pandemic, from March 16, 2020 to September 30, 2021. Results. One-thousand patients were identified, 501 patients were distributed in the pre-pandemic group and 499 in the pandemic group. The average consultation time from the time of onset of symptoms to consultation was 43 hours in the prepandemic group and almost 45 hours in the pandemic. Discussion. Despite the restrictions due to the disease caused by the new coronavirus and the fear that may existed due to contagion, in our center there was no evidence of a change in the management and presentation of patients diagnosed with acute appendicitis


Subject(s)
Humans , Appendicitis , COVID-19 , Intraoperative Complications , Appendectomy , Postoperative Complications , Coronavirus Infections , Pandemics
3.
Revista Colombiana de Reumatología ; 2021.
Article in Spanish | EuropePMC | ID: covidwho-1564112

ABSTRACT

Introducción: Se han descrito casos de patologías autoinmunes de inicio posterior a la infección por el virus SARS-CoV-2. La relación causal aún no es clara, por lo que es importante la construcción de la literatura frente a esta incógnita. Presentación de caso: reportamos el caso de una mujer de 44 años de edad quien 18 días luego de cursar con infección por SARS-CoV-2 sin hipoxemia, presenta poliartralgias inflamatorias y paraclínicos compatibles con un diagnóstico de artritis reumatoide. Conclusión: este caso refuerza la posibilidad de una relación causal entre ambas entidades.

4.
Revista Colombiana de Reumatología ; 2021.
Article in Spanish | ScienceDirect | ID: covidwho-1559034

ABSTRACT

Resumen Introducción: Se han descrito casos de patologías autoinmunes de inicio posterior a la infección por el virus SARS-CoV-2. La relación causal aún no es clara, por lo que es importante la construcción de la literatura frente a esta incógnita. Presentación de caso: reportamos el caso de una mujer de 44 años de edad quien 18 días luego de cursar con infección por SARS-CoV-2 sin hipoxemia, presenta poliartralgias inflamatorias y paraclínicos compatibles con un diagnóstico de artritis reumatoide. Conclusión: este caso refuerza la posibilidad de una relación causal entre ambas entidades. Introduction: Cases of autoimmune pathologies with onset after infection by the SARS-CoV-2 virus have been described. The causal relationship is not yet clear. Case presentation: We report the case of a 44-year-old woman who, 18 days after presenting with SARS-CoV-2 infection without hypoxaemia, presented with a clinical picture compatible with a diagnosis of rheumatoid arthritis. Conclusion: This case reinforces the possibility of a causal relationship between both entities.

5.
Rheumatol Int ; 42(1): 41-49, 2022 01.
Article in English | MEDLINE | ID: covidwho-1503927

ABSTRACT

The objective of our study was to describe knowledge, attitudes and practices of Latin-American rheumatology patients regarding management and follow-up of their disease during COVID-19 pandemic. A cross-sectional observational study was conducted using a digital anonymous survey. Rheumatic patients ≥ 18 years from non-English-speaking PANLAR countries were included. Our survey included 3502 rheumatic patients living in more than 19 Latin-American countries. Median age of patients was 45.8(36-55) years and the majority (88.9%) was female. Most frequently self-reported disease was rheumatoid arthritis (48.4%). At least one anti-rheumatic treatment was suspended by 23.4% of patients. Fear of contracting SARS-Cov2 (27.7%) and economic issues (25%) were the most common reasons for drug discontinuation. Self-rated disease activity increased from 30 (7-50) to 45 (10-70) points during the pandemic. Communication with their rheumatologist during the pandemic was required by 55.6% of patients, mainly by telephone calls (50.2%) and social network messages (47.8%). An adequate knowledge about COVID-19 was observed in 43% of patients. Patients with rheumatic diseases in Latin America were negatively affected by the COVID-19 pandemic. An increase in self-rated disease activity, a reduction in medication adherence, and hurdles for medical follow-up were reported. Teleconsultation was perceived as a valid alternative to in-person visits during the pandemic.


Subject(s)
Antirheumatic Agents/therapeutic use , COVID-19 , Health Knowledge, Attitudes, Practice , Rheumatic Diseases/drug therapy , Cross-Sectional Studies , Humans , Latin America , Pandemics
6.
J Rheumatol ; 48(10): 1616-1622, 2021 10.
Article in English | MEDLINE | ID: covidwho-1335273

ABSTRACT

OBJECTIVE: To describe the effect of the coronavirus disease 2019 (COVID-19) pandemic on Latin American rheumatologists from a professional, economic, and occupational point of view. METHODS: We conducted an observational cross-sectional study using an online survey sent to rheumatologists of each non-English-speaking country member of the Pan American League of Rheumatology Associations (PANLAR). A specific questionnaire was developed. RESULTS: Our survey included 1097 rheumatologists from 19 Latin American countries. Median (IQR) age of respondents was 48 (40-59) years and 618 (56.3%) were female. Duration of practice since graduation as a rheumatologist was 17 years, and 585 (53.3%) were aged < 50 years. Most rheumatologists worked in private practice (81.8%) and almost half worked in institutional outpatient centers (55%) and inpatient care (49.9%). The median number of weekly hours (IQR) of face-to-face practice before the pandemic was 27 (15-40) hours, but was reduced to 10 (5-20) hours during the pandemic. Telehealth was used by 866 (78.9%) respondents during the pandemic. Most common methods of communication were video calls (555; 50.6%), telephone calls (499; 45.5%), and WhatsApp voice calls (423; 38.6%). A reduction in monthly wages was reported by 946 (86.2%) respondents. Consultation fees also were reduced and 88 (8%) rheumatologists stated they had lost their jobs. A reduction in patient adherence to medication was reported by nearly 50% of respondents. Eighty-one (7.4%) rheumatologists received a COVID-19 diagnosis and 7 (8.6%) of them were hospitalized. CONCLUSION: The COVID-19 pandemic has reshaped rheumatology practice in Latin America and has had a profound effect on rheumatologists' behaviors and clinical practice.


Subject(s)
COVID-19 , Rheumatology , COVID-19 Testing , Cross-Sectional Studies , Female , Humans , Latin America/epidemiology , Middle Aged , Pandemics , SARS-CoV-2 , Surveys and Questionnaires
7.
Reumatol Clin (Engl Ed) ; 16(6): 437-446, 2020.
Article in English, Spanish | MEDLINE | ID: covidwho-725466

ABSTRACT

OBJECTIVE: To produce recommendations for patients with rheumatological diseases receiving immunomodulatory and immunosuppressive therapies (conventional drugs, biologicals, and small molecules) during the COVID-19 pandemic. MATERIALS AND METHODS: The recommendations were determined using the Delphi method as an agreement tool. A panel of experts was formed, with academic backgrounds and research experience in rheumatology. A literature search was conducted and 42 questions were generated. The level of agreement was made with 80% of approval by the participants. RESULTS: A group of eleven rheumatologists from 7 cities in the country participated. The response rate was 100% for the three consultation rounds. In the first round, agreement was reached on 35 questions, on 37 in the second round, and on 42 questions in the third round. CONCLUSION: The recommendation for the majority of the pharmacological treatments used in rheumatology is to continue with immunomodulatory or immunosuppressive therapies in patients who do not have the infection, and to suspend it in patients with a diagnosis of SARS-CoV-2/COVID-19.


Subject(s)
Antirheumatic Agents/therapeutic use , Betacoronavirus , Coronavirus Infections/complications , Pandemics , Pneumonia, Viral/complications , Rheumatic Diseases/complications , Adult , Anti-Inflammatory Agents, Non-Steroidal/adverse effects , Anti-Inflammatory Agents, Non-Steroidal/therapeutic use , Antibodies, Monoclonal/adverse effects , Antibodies, Monoclonal/therapeutic use , Antimalarials/adverse effects , Antimalarials/therapeutic use , Antirheumatic Agents/adverse effects , Biological Products/adverse effects , Biological Products/therapeutic use , COVID-19 , Clinical Trials as Topic , Colombia , Coronavirus Infections/drug therapy , Delphi Technique , Drug Interactions , Drug Repositioning , Glucocorticoids/adverse effects , Glucocorticoids/therapeutic use , Humans , Immunoglobulins, Intravenous/therapeutic use , Immunologic Factors/adverse effects , Immunologic Factors/therapeutic use , Immunosuppressive Agents/adverse effects , Immunosuppressive Agents/therapeutic use , Multicenter Studies as Topic , Pneumonia, Viral/drug therapy , Rheumatic Diseases/drug therapy , SARS-CoV-2 , COVID-19 Drug Treatment
8.
Rev. colomb. reumatol ; 27(3): 230-241, jul.-set. 2020. tab, graf
Article in Spanish | WHO COVID, LILACS (Americas) | ID: covidwho-597132

ABSTRACT

RESUMEN Objetivo: Generar las recomendaciones para la atención de pacientes con enfermedades reumáticas que reciben terapias inmunomoduladoras e inmunosupresoras (fármacos convencionales, biológicos y moléculas pequeñas) durante la pandemia por COVID-19. Materiales y métodos: Las recomendaciones se realizaron utilizando el método Delphi como herramienta de acuerdo. Se conformó un panel de expertos con trayectoria académica y experiencia en investigación en reumatología. Se realizó la búsqueda de la literatura y se generó el cuestionario del ejercicio Delphi conformado por 42 preguntas. El grado de acuerdo se logró con el 80% de aprobación de los participantes. Resultados: Se conformó un grupo de 11 reumatólogos de 7 ciudades del país. La tasa de respuesta fue del 100% para las 3 rondas de consulta. En la primera ronda se logró acuerdo en 35 preguntas, en la segunda ronda 37 y en la tercera ronda se logró el acuerdo de las 42 preguntas. Conclusión: La recomendación para la mayoría de los tratamientos inmunomoduladores utilizados en reumatología es continuar con las terapias en pacientes que no tengan la infección y suspenderlas en aquellos con diagnóstico de SARS-CoV-2/COVID-19.


ABSTRACT Objective: To produce recommendations for patients with rheumatological diseases receiving immunomodulatory and immunosuppressive therapies (conventional drugs, biologicals, and small molecules) during the COVID-19 pandemic. Materials and methods: The recommendations were determined using the Delphi method as an agreement tool. A panel of experts was formed, with academic backgrounds and research experience in rheumatology. A literature search was conducted and 42 questions were generated. The level of agreement was made with 80% of approval by the participants. Results: A group of eleven rheumatologists from 7 cities in the country participated. The response rate was 100% for the three consultation rounds. In the first round, agreement was reached on 35 questions, on 37 in the second round, and on 42 questions in the third round. Conclusion: The recommendation for the majority of the pharmacological treatments used in rheumatology is to continue with immunomodulatory or immunosuppressive therapies in patients who do not have the infection, and to suspend it in patients with a diagnosis of SARS-CoV-2/COVID-19.


Subject(s)
Humans , Patients , Rheumatic Diseases , COVID-19 , Therapeutics , Delphi Technique , Adult
SELECTION OF CITATIONS
SEARCH DETAIL